At $2 a share, Novartis would be paying more than $1.2 billion for Cell Therapeutics! And what would Novartis get for that mountain of cash? A me-too chemotherapy drug just body-checked into oblivion by the FDA and its advisory panel? How about a reformulation of a generic chemotherapy drug that has failed multiple phase III trials and was rejected by European regulators last year?
Oh, how enticing!
Big Pharma tends to get suckered into dumb deals, but no one, Novartis included, is that stupid.
Update: Cell Therapeutics held a conference call Thursday night. All I'll say about the call is that it robbed me of 30 minutes of my life that I'll never get back.
ARoy emails, "What do you feel about the prospects of Spectrum Pharmaceuticals (SPPI)? It's been a while since you've have written about the company. Do you consider Spectrum shares are currently undervalued or at least fairly valued?" Spectrum has traded relatively sideways since late last year because investors still aren't sure if the company is going to turn the lymphoma drug Zevalin into a profitable drug. Monday, Spectrum said it was delaying the release of financial results for the fourth quarter and full year 2009 because it needs more time to complete its accounting work. Spectrum said it will post a higher net loss in 2009 than the previous year, but that's not a surprise at all. More important for Spectrum and its stock price are sequential quarterly sales gains for Zevalin. Third quarter sales totaled $4.7 million, up 42% from the second quarter. Spectrum doesn't have enough analyst coverage to compile a good consensus, but Morgan Joseph's analyst is looking for fourth quarter Zevalin sales of $5.6 million. Don't expect Spectrum's stock to surge even if Zevalin posts healthy sequential growth in the fourth quarter. That would be nice, but I think Spectrum is under the gun to produce consistent Zevalin sales growth over a longer time period before all the doubts about the drug and its commercial potential are lifted. Investors also want evidence that doctors are using Zevalin in more patients and that sales growth is not just coming from price increases. The FDA label for first-line use in non-Hodgkin's lymphoma granted last September was a big help in that effort, but it's still up to Spectrum to generate meaningful sales.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV